Interesting finding from BerlinCures in Long Covid showing the presence of functional G protein coupled autoantibodies in patients. Important point is the assay looks at functional autoantibodies, unlike ELISA based techniques. Also the company has a product in development at the phase 2 level (BC007) for the treatment of heart failure due to beta1 autoantibodies. BC007 is also active against a range of other autoantibodies including those involved in ME & POTS. Though I can't believe that all 3 of these conditions are only autoantibody driven as cell mediated autoimmunity almost certainly plays a part it is another piece of the dysautonomia jigsaw with the bonus of a treatment in early development.
A bit of the background on the drug, which is an aptamer can be found here.
atlasofscience.org
Just re-read the article and replace the words cardiomyopathy with ME or POTS or Long covid and you can see how BC007 has potential as a treatment for conditions with autonomic nervous system (all G protein coupled) autoantibodies.
A bit of the background on the drug, which is an aptamer can be found here.
BC007, first steps of this new drug on the way for future treatment of patients with cardiomyopathy – Atlas of Science
Dilated cardiomyopathy (DCM) is a disease of the heart in which the heart chambers stretch and thin (dilate). Under this condition, the heart and cannot pump enough blood needed by the other organs need.
Just re-read the article and replace the words cardiomyopathy with ME or POTS or Long covid and you can see how BC007 has potential as a treatment for conditions with autonomic nervous system (all G protein coupled) autoantibodies.
![ME/CFS lecture | Dr Nancy Klimas | 2011 [Chronic Fatigue Syndrome / SEID / New Zealand] - YouTube](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
